Nivalis Therapeutics, Inc. Stock Shares Climb Up On Merger Announcement
Ticker.tv News | Apr 19, 2017 07:54AM ET
Nivalis Therapeutics Inc (NASDAQ:NVLS)
Nivalis Therapeutics, Inc. (NVLS), a pharmaceutical company yesterday announced a merger with Alpine Immune Sciences. The post merger company will be based in Seattle and is expected to close during the third quarter of this year.
h3 Nivalis Therapeutics, Inc. CEO’s Comments/h3Howard Furst, Chairman of the Board of Nivalis said,
h3 NVLS Technical Analysis/h3
We believe this transaction with Alpine is an exciting path forward to advance important new therapies for patients and to create significant value for shareholders. Alpine, which has discovered novel ways to target the immune synapse, is led by a solid and experienced management team that has successfully brought immunotherapies to market. Business Wire
NVLS opened trading yesterday at $2.75 which was down from the previous day’s trading close of $2.77. NVLS closed trading yesterday at $2.64 and spiked up after market to $3.20, equivalent to a 21% increase from the closing price. Taking a look at the daily chart we can see that the last time NVLS traded above these levels we have to go back to March 13th when it traded at highs of $3.63.
Taking a closer look at the daily chart we can see that before the spike up NVLS had been in an overall downward trend dating back to November 28th, 2016 when it traded at $6.25. NVLS has a float of 8.39 million shares and traded below the normal daily trading volume on Tuesday.
For trading purposes, I would like to see NVLS open trading on Wednesday above $3.00 and if it does I would be looking to take a long position with a relative volume at a 2 or higher. My stop loss would be $0.10 from my entry position fearing anything more than that and the stock would start to fill in the gap up.
h3 Company Profile/h3Nivalis Therapeutics, Inc., incorporated on March 30, 2007, is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.
The Company’s S-nitrosoglutathione reductase (GSNOR) inhibitors selectively target GSNOR. Depleted levels of S-nitrosoglutathione (GSNO) have been associated with CF, asthma, inflammatory bowel diseases and certain cardiovascular diseases. The Company’s lead product candidate, cavosonstat (N91115), is a small molecule inhibitor of GSNOR. cavosonstat is a pill that is in two Phase II clinical trials intended to address a defect in CF transmembrane conductance regulator (CFTR), resulting from mutations in the CFTR gene. Its preclinical studies have shown that cavosonstat is a selective and reversible inhibitor of GSNOR.
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.